ArticlePediatric blood & cancer2020
Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.
Article in Pediatric blood & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232.Leukemia · 2024Trial
- Review
- Genetic predisposition of Asparaginase-induced hypertriglyceridemia in children with acute lymphoblastic leukemia: Two case reports and review of literature.World journal of clinical pediatrics · 2026Article
- Pegaspargase-associated cerebral venous sinus thrombosis: risk factors and anticoagulation management in pediatric acute lymphoblastic leukemia-a case series.Translational pediatrics · 2026Article
- Asperginase-based chemotherapy regimen for acute lymphoblastic leukemia: A cohort study with promising outcomes on adults.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026Article
- Hypertriglyceridemia During Anticancer Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia - A Nationwide Experience.Cancer management and research · 2026Article
- Severe asparaginase-associated hypertriglyceridemia in pediatric acute lymphoblastic leukemia: a single-center experience.Frontiers in oncology · 2026Article
- Article
- Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2025Review
- Acute therapy-related toxicities in pediatric acute lymphoblastic leukemia.Haematologica · 2025Review
- Sex and Gender in Myeloid and Lymphoblastic Leukemias and Multiple Myeloma: From Molecular Mechanisms to Clinical Outcomes.Current oncology (Toronto, Ont.) · 2025Review
- Induction of Cyp2e1 contributes to asparaginase-induced hepatocyte sensitization to lipotoxicity.Acta pharmaceutica Sinica. B · 2025Article
- Acute Pancreatitis Caused by Pegylated (PEG)-Asparaginase Associated With Severe Hypertriglyceridemia.Cureus · 2024Article
- Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report.Therapeutic advances in hematology · 2024Article
- Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities.Briefings in bioinformatics · 2023Article
- Parenteral Nutrition in the Pediatric Oncologic Population: Are There Any Sex Differences?Nutrients · 2023Article
- Article
- [Osteonecrosis-severe side effect of treatment for acute lymphoblastic leukemia].Orthopadie (Heidelberg, Germany) · 2022Review
- Apolipoproteins-New Biomarkers of Overweight and Obesity among Childhood Acute Lymphoblastic Leukemia Survivors?International journal of molecular sciences · 2022Article
- Haematological Drugs Affecting Lipid Metabolism and Vascular Health.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGlucocorticoids and asparaginase, used to treat acute lymphoblastic leukemia (ALL), can cause hypertriglyceridemia. We compared triglyceride levels, risk factors, and associated toxicities in two ALL trials at St. Jude Children's Research Hospital with identical glucocorticoid regimens, but different asparaginase formulations. In Total XV (TXV), native Escherichia coli l-asparaginase was front-line therapy versus the pegylated formulation (PEG-asparaginase) in Total XVI (TXVI). PROCEDURE: Patients enrolled on TXV (n = 498) and TXVI (n = 598) were assigned to low-risk (LR) or standard/high-risk (SHR) treatment arms (ClinicalTrials.gov identifiers: NCT00137111 and NCT00549848). Triglycerides were measured four times and were evaluable in 925 patients (TXV: n = 362; TXVI: n = 563). The genetic contribution was assessed using a triglyceride polygenic risk score (triglyceride-PRS). Osteonecrosis, thrombosis, and pancreatitis were prospectively graded.
resultsThe largest increase in triglycerides occurred in TXVI SHR patients treated with dexamethasone and PEG-asparaginase (4.5-fold increase; P <1 × 10
conclusionTriglycerides were affected more by PEG-asparaginase than native l-asparaginase, by asparaginase more than dexamethasone, and by drug effects more than genetics. It is not clear whether triglycerides contribute to thrombosis and osteonecrosis or are biomarkers of the toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.